Your browser doesn't support javascript.
loading
Appropriateness of implantable cardioverter-defibrillator device implants in the United States.
Yousuf, Omair K; Kennedy, Kevin; Russo, Andrea; Varosy, Paul; Lindsay, Bruce D; Steinberg, Benjamin; Atwater, Brett D; Calkins, Hugh; Spertus, John A.
Afiliação
  • Yousuf OK; Saint Luke's Mid America Heart Institute, Kansas City, Missouri; Carient Heart & Vascular, Manassas, Virginia; Inova Heart and Vascular Institute, Fairfax, Virginia; University of Virginia Health, Manassas, Virginia. Electronic address: Omair.Yousuf@gmail.com.
  • Kennedy K; Saint Luke's Mid America Heart Institute, Kansas City, Missouri.
  • Russo A; Cooper Health, Voorhees, New Jersey.
  • Varosy P; University of Colorado, Denver, Colorado.
  • Lindsay BD; Cleveland Clinic, Cleveland, Ohio.
  • Steinberg B; University of Utah, Salt Lake City, Utah.
  • Atwater BD; Saint Luke's Mid America Heart Institute, Kansas City, Missouri; Inova Heart and Vascular Institute, Fairfax, Virginia.
  • Calkins H; Johns Hopkins Medical Institution, Baltimore, Maryland.
  • Spertus JA; Saint Luke's Mid America Heart Institute, Kansas City, Missouri.
Heart Rhythm ; 21(4): 397-407, 2024 Apr.
Article em En | MEDLINE | ID: mdl-38123044
ABSTRACT

BACKGROUND:

The appropriate use criteria (AUCs) are a diverse group of indications aimed to better evaluate the benefits of implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy.

OBJECTIVE:

The purpose of this study was to quantify the proportion of ICD and cardiac resynchronization therapy with defibrillator (CRT-D) implants as appropriate, may be appropriate (MA), or rarely appropriate (RA) on the basis of the AUC guidelines.

METHODS:

This is a multicenter retrospective study of patients within the National Cardiovascular Data Registry undergoing ICD implantation between April 2018 and March 2019 at >1500 US hospitals. The appropriateness of ICD implants was adjudicated using the AUC.

RESULTS:

Of 309,318 ICDs, 241,438 were primary prevention implants (78.1%) and 67,880 secondary prevention implants (21.9%); 243,532 (79%) were mappable to the AUC. For primary prevention, 185,431 ICDs (96.4%) were appropriate, 5660 (2.9%) MA, and 1205 (0.6%) RA. For secondary prevention, 47,498 ICDs (92.7%) were appropriate, 2581 (5%) MA, and 1157 (2.3%) RA. A significant number of RA devices were implanted in patients with New York Heart Association class IV heart failure who were ineligible for advanced therapies (53.9%) and those with myocardial infarction within 40 days (18.1%). The appropriateness of the pacing lead was more variable, with 48,470 dual-chamber ICD implants (62%) being classified as appropriate, 29,209 (37.4%) MA, and 448 (0.6%) RA. Among CRT-D implants, 63,848 (82.2%) were appropriate, 9900 (12.7%) MA, and 3940 (5.1%) RA for left ventricular pacing. A total of 99,754 implants were deemed appropriate but excluded from Centers for Medicare & Medicaid Services National Coverage Determination. More than 92% of hospitals had an RA implant rate of <4%.

CONCLUSION:

In this large national registry, 95% of mappable ICD and CRT-D implants were considered appropriate, with <2% of RA implants. Nearly 100,000 appropriate implants are excluded by Centers for Medicare & Medicaid Services National Coverage Determination.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Marca-Passo Artificial / Desfibriladores Implantáveis / Terapia de Ressincronização Cardíaca / Insuficiência Cardíaca Limite: Aged / Humans País/Região como assunto: America do norte Idioma: En Revista: Heart Rhythm Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Marca-Passo Artificial / Desfibriladores Implantáveis / Terapia de Ressincronização Cardíaca / Insuficiência Cardíaca Limite: Aged / Humans País/Região como assunto: America do norte Idioma: En Revista: Heart Rhythm Ano de publicação: 2024 Tipo de documento: Article